A Major Milestone for AsymBio: Shanghai Fengxian Commercial Production Base Is Officially Operational!
We are thrilled to announce the official launch of our Shanghai Fengxian Commercial Production Base - our third core commercial hub alongside Jinshan and Zhangjiang, marking a game-changing leap for our global biologics CDMO service network.
Spanning 130,000+ square meters, this cutting-edge facility is built and verified for NDCs(including ADCs), antibodies/TCEs, and recombinant proteins.
Key highlights for global partners:
--Phase I-A (Antibody Capacity): Fully operational with 200L/500L/2000L single-use bioreactors and 20㎡ lyophilizers, ready to support IND and late-stage commercial projects.
--Phase I-B (NDC Capacity): To be Launched in Jan 2026 with specialized conjugation reactors and multi-scale lyophilizers, delivering flexible, manufacturing solutions.
--Compliance with NMPA, FDA, and EMA standards, ensuring seamless global market access for our partners.
This is not just a new facility—it is our commitment to accelerating your path from innovation to patient impact. With scalable capacity and end-to-end CDMO capabilities, we're here to turn your groundbreaking biologics into life-changing therapies!
